Grifols and biotechnology startup, FcR Therapeutics, have agreed to collaborate on recombinant nanobodies to treat autoimmune diseases.  The nanobodies, which are small highly specialised antibody fragments, would act to restrain or inhibit the activity of certain Fc receptors (FcR), naturally occurring proteins found on the surface of immune cells that play a crucial role in […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!